Printer Friendly

Tonix Pharmaceuticals partners with USAMMDA to examine TNX-102 SL for post-traumatic stress disorder in warfighters.

M2 EQUITYBITES-December 8, 2015-Tonix Pharmaceuticals partners with USAMMDA to examine TNX-102 SL for post-traumatic stress disorder in warfighters

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Medicine company Tonix Pharmaceuticals Holding (NASDAQ:TNXP) disclosed on Monday the launch of a Cooperative Research and Development Agreement (CRADA) to explore expansion and potential development of its investigational new drug, TNX-102 SL, for treating military-related post-traumatic stress disorder (PTSD).

The company has signed the agreement with the US Army Medical Materiel Development Activity (USAMMDA)

USAMMDA is the Department of Defense's (DoD) advanced development activity for products designed to protect and preserve the lives of Warfighters. USAMMDA develops new drugs, vaccines and medical support equipment that enhance readiness, and ensures the provision of the highest quality medical care to the DoD.

TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a small, rapidly dissolving tablet containing very low dose cyclobenzaprine in a eutectic formulation for sublingual (under the tongue) administration and rapid absorption into the blood stream. It is designed for use at bedtime to improve sleep quality and to have a tolerability profile that supports chronic treatment, concluded Tonix.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 8, 2015
Words:195
Previous Article:Sucampo buys R-Tech Ueno for USD275m.
Next Article:Comtech Telecommunications announces commencement of tender offer for TeleCommunication Systems.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters